Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- VYGR
- Price
- 4.10
- Stock movement up
- +0.33 (8.75%)
- Company name
- Voyager Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 227.96M
- Ent value
- 251.32M
- Price/Sales
- 7.28
- Price/Book
- 1.04
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -1.48%
- 1 year return (CAGR)
- -21.46%
- 3 year return (CAGR)
- -23.63%
- 5 year return (CAGR)
- -14.40%
- 10 year return (CAGR)
- -12.03%
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VYGR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.28 |
| Price to Book | 1.04 |
| EV to Sales | 8.03 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.60M |
| EPS (TTM) | -2.16 |
| FCF per share (TTM) | -2.02 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 31.32M |
| Gross profit (TTM) | 31.32M |
| Operating income (TTM) | -140.21M |
| Net income (TTM) | -126.78M |
| EPS (TTM) | -2.16 |
| EPS (1y forward) | -1.56 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -447.73% |
| Profit margin (TTM) | -404.85% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 45.13M |
| Net receivables | 4.04M |
| Total current assets | 219.59M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 288.31M |
| Accounts payable | 2.12M |
| Short/Current long term debt | 38.37M |
| Total current liabilities | 35.49M |
| Total liabilities | 68.49M |
| Shareholder's equity | 219.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -116.73M |
| Capital expenditures (TTM) | 2.13M |
| Free cash flow (TTM) | -118.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -57.67% |
| Return on Assets | -43.97% |
| Return on Invested Capital | -55.69% |
| Cash Return on Invested Capital | -52.21% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.79 |
| Daily high | 4.22 |
| Daily low | 3.79 |
| Daily Volume | 840K |
| All-time high | 31.31 |
| 1y analyst estimate | 15.00 |
| Beta | 1.39 |
| EPS (TTM) | -2.16 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 10 Mar 2026 |
Downside potential
Loading...
Downside potential data
| VYGR | S&P500 | |
| Current price drop from All-time high | -86.91% | -0.89% |
| Highest price drop | -92.11% | -56.47% |
| Date of highest drop | 5 Oct 2021 | 9 Mar 2009 |
| Avg drop from high | -66.08% | -10.84% |
| Avg time to new high | 151 days | 12 days |
| Max time to new high | 1982 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
227.96M
Marketcap category
Small-cap
Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Employees
172
Investor relations
-
SEC filings
CEO
G. Andre Turenne
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page